The Canadian journal of urology最新文献

{"title":"A comprehensive review about sperm-oocyte interactions and key activation factors of fertilization in mammals.","authors":"Soukaina Azil, Yassmine Louanjli, Noureddine Louanjli, Moncef Benkhalifa, Bouchra Ghazi","doi":"10.32604/cju.2025.069420","DOIUrl":"10.32604/cju.2025.069420","url":null,"abstract":"<p><p>Mammalian fertilization involves the migration of spermatozoa through the female reproductive system. Early embryonic development is a consequence of several steps and signaling pathways being activated, as well as biochemical and morphological modifications of spermatozoa that enable them to penetrate the membrane of mature oocytes. There are some crucial steps known to clearly explain the process of fertilization, starting with hyperactivation of spermatozoa, mutual recognition, and binding of gametes mediated by receptors located on the surface membranes of both gametes. The final step is followed by oocyte activation, which is primarily triggered via sperm-derived factors, inducing a sharp increase in intracellular calcium levels, eventually leading to polyspermy block. This review integrates current knowledge of the molecular and physiological events governing fertilization, emphasizing how ion regulation and signaling pathways converge to enable sperm function and oocyte activation. Special attention is given to sperm-derived factors such as phospholipase C zeta (PLCζ) and post-acrosomal sheath WW domain-binding protein (PAWP), which play essential roles in triggering calcium release and supporting early embryonic development.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"51-62"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suprapubic transvesical adenoma resection of the prostate (STAR-P): step-by-step technique.","authors":"Christian Gozzi, Bruno Bucca, Orietta Dalpiaz, Aldo Brassetti, Luca Matteo Gobbi, Greta Basile, Miroslav Djordjevic","doi":"10.32604/cju.2025.068035","DOIUrl":"10.32604/cju.2025.068035","url":null,"abstract":"<p><strong>Overview: </strong>Surgical management of benign prostatic hyperplasia (BPH) has evolved significantly, incorporating various minimally invasive procedures aimed at reducing morbidity and optimizing patient outcomes. Despite advancements, transurethral approaches continue to pose risks such as urethral strictures and urinary incontinence due to mechanical and thermal stress. To address these limitations, the Suprapubic Transvesical Adenoma Resection of the Prostate (STAR-P) was developed, offering a direct suprapubic route that bypasses the urethra entirely. Recent studies have validated STAR-P as both feasible and safe, emphasizing advantages such as enhanced visualization of the urinary sphincter, minimized urethral trauma, effective hemostasis, and reduced operative stress. The procedure utilizes specially designed instrumentation, including a large-caliber bipolar resectoscope (42 Fr), allowing the efficient removal of substantial adenoma tissue in fewer resection passes compared to traditional methods.</p><p><strong>Objectives: </strong>This article provides a comprehensive, step-by-step description of the STAR-P technique. The primary objective is to detail patient selection criteria, preoperative assessments, procedural steps including mini-open suprapubic access, specialized instrumentation usage, resection techniques, and postoperative management protocols. Highlighting technical considerations and procedural innovations aims to inform urologists about the potential benefits of STAR-P, particularly in patients at higher risk for urethral complications or those with large prostate volumes. By documenting the procedural intricacies and outcomes clearly and thoroughly, we seek to encourage informed adoption of STAR-P as an alternative, effective surgical approach for managing benign prostatic hyperplasia, thus contributing to the evolving landscape of minimally invasive urological surgery.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"75-82"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of vaginal androgen combined with pelvic floor muscle training for stress urinary incontinence in postmenopausal women: a randomized-controlled trial.","authors":"Yingxiu Chen, Zhongyu Ren, Jiasheng Yan, Yang Yu","doi":"10.32604/cju.2025.069041","DOIUrl":"10.32604/cju.2025.069041","url":null,"abstract":"<p><strong>Objectives: </strong>Postmenopausal women with stress urinary incontinence (SUI) exhibit low androgen expression. This study aimed to evaluate the efficacy and safety of vaginal androgen combined with pelvic floor muscle training (PFMT) in the treatment of SUI in postmenopausal women.</p><p><strong>Methods: </strong>Postmenopausal women with SUI were recruited from Hainan West Central Hospital between January 2024 and March 2025. Participants were randomly assigned in a double-blind manner to receive either vaginal androgen cream combined with PFMT (treatment group) or a visually identical placebo cream (without androgens) combined with PFMT (control group). The vaginal cream was applied to the vaginal wall at a dose of 0.5 g per application, twice weekly for a total of 10 applications, while PFMT was conducted for 8 weeks. The clinical efficacy and safety were compared between the two groups.</p><p><strong>Results: </strong>A total of 61 patients were finally enrolled, with 31 in the treatment group and 30 in the control group. At both 3-month and 6-month follow-ups, the treatment group demonstrated significantly lower values in daily pad usage (p < 0.05), 24-h pad test scores (p < 0.05), and ICIQ-UI SF scores (p < 0.05) compared to the control group. The improvement rate of urinary incontinence was significantly higher in the treatment group (p < 0.05). Compared to baseline, the treatment group showed statistically significant reductions in all three outcome measures (all p < 0.05). No severe adverse events were reported in either group during the treatment period.</p><p><strong>Conclusions: </strong>Androgen therapy combined with PFMT significantly improved the urinary incontinence remission rate in postmenopausal women with SUI, with no severe adverse effects observed. These findings suggest that androgen therapy may represent a novel therapeutic approach for SUI management in postmenopausal women.</p><p><strong>Clinical trial registration number: </strong>ChiCTR2300078752 in the Chinese Clinical Trial Registry.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"143-154"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clear cell sarcoma of the kidney with inferior vena cava tumor thrombus in a pediatric patient: a case report.","authors":"Bo Yin, Xingyu Long, Zhi Wang, Feng Ning, Kan Wang, Jun He","doi":"10.32604/cju.2025.067189","DOIUrl":"10.32604/cju.2025.067189","url":null,"abstract":"<p><strong>Background: </strong>Clear cell sarcoma of the kidney (CCSK) is a rare and highly aggressive pediatric renal malignancy with a marked propensity for metastatic spread. Cases of CCSK associated with inferior vena cava (IVC) tumor thrombus (IVCTT) are exceptionally uncommon in the literature. We report a case of CCSK with IVCTT in a 15-month-old male infant.</p><p><strong>Case description: </strong>We reported a case admitted in May 2020 for a 3-day history of fever and hematuria. Abdominal CT revealed an unevenly enhanced mass and low-density shadows within the IVC. The diagnosis of CCSK was confirmed via needle biopsy. The patient received 4 cycles of adjuvant chemotherapy. The initial surgery lasted 10 h with 600 mL blood loss, and primary closure was achieved. Postoperative management included 6 cycles of radiotherapy and 5 cycles of chemotherapy. In March 2022, CT detected IVCTT recurrence, requiring surgical intervention involving thrombus removal and partial IVC resection. This procedure lasted 8 h with 300 mL blood loss, followed by 5 additional chemotherapy cycles. The patient showed no sign of IVC obstruction, including varicose veins or lower limb edema, and maintained renal function throughout follow-up. However, Intracranial metastases were detected 15 months postoperatively. After the family opted against additional treatment, the patient succumbed to the disease.</p><p><strong>Conclusions: </strong>The management of CCSK associated with IVCTT should include consideration of IVC thrombectomy. In case of recurrent IVCTT with preserved collateral circulation, combined thrombus excision and partial IVC resection may be warranted.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"201-210"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence assisted 3D in the robotic urooncology? A systematic review and narrative synthesis of current applications, challenges and future directions.","authors":"Bara Barakat, Bilal Al-Absi, Boris Hadaschik, Christian Rehme, Samer Schakaki, Joerg Bauer","doi":"10.32604/cju.2026.071284","DOIUrl":"10.32604/cju.2026.071284","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI)-assisted three-dimensional (3D) surgical platforms, integrated with augmented reality, have the potential to improve intraoperative anatomical recognition and provide surgeons with an immersive, dynamic operating environment during uro-oncological procedures. This review aims to examine the current applications of AI in robotic uro-oncology, with a particular focus on its role in facilitating intraoperative navigation during complex surgeries.</p><p><strong>Methods: </strong>A systematic literature search was performed across PubMed, the National Library of Medicine, MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and Google Scholar to identify relevant studies published up to July 2025. The search strategy incorporated a predefined set of keywords, including AI, machine learning, radical prostatectomy (RP), robotic-assisted radical prostatectomy (RARP), robot-assisted partial nephrectomy (RAPN), and robot-assisted radical cystectomy (RARC). Only clinical trials, full-text peer-reviewed publications, and original research articles were included. Studies were eligible for inclusion if they evaluated or described applications of AI in RARP, RAPN, or RARC.</p><p><strong>Results: </strong>Technological advancements have substantially transformed the field of uro-oncologic surgery. In particular, AI and AI-assisted intraoperative navigation in RARP demonstrate considerable potential to objectively assess surgical performance and predict clinical outcomes. In RAPN, the adoption of preoperative, interactive 3D virtual models for surgical planning has influenced surgical decisions, thus, enhanced precision in resection planning correlates with superior nephron-sparing outcomes and optimized selective clamping. AI applications in RARC, techniques such as augmented reality (AR) can overlay critical information on the surgical field, by facilitating navigation through complex anatomical planes and enhancing identification of critical structures.</p><p><strong>Conclusion: </strong>AI appears to enhance robotic uro-oncologic procedures by increasing operative precision and supporting individualised surgical treatment strategies.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"105-116"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uretero-enteric strictures after cystectomy: revealing the modifiable risk factors.","authors":"Abdelkader Akkad, Franck Bruyere, Ali Bourgi","doi":"10.32604/cju.2025.069546","DOIUrl":"10.32604/cju.2025.069546","url":null,"abstract":"<p><strong>Objectives: </strong>Uretero-enteric strictures are feared complications following cystectomy. Despite surgical advancements, particularly the rise of robot-assisted approaches, the risk factors associated with these strictures remain poorly defined. This study aimed to identify the risk factors associated with uretero-enteric anastomotic strictures after cystectomy, according to the surgical approach and type of urinary diversion (extracorporeal vs. intracorporeal).</p><p><strong>Methods: </strong>We conducted a single-center retrospective study including 340 patients who underwent cystectomy between 2016 and 2024 at Tours University Hospital. Clinical, biological, perioperative, and postoperative data were analyzed. The occurrence of a uretero-ileal anastomotic stricture was defined radiologically by a uretero-hydronephrosis ≥20 mm. We constructed and analyzed a learning curve for robotic surgery with intracorporeal urinary diversion.</p><p><strong>Results: </strong>Strictures occurred in 60 patients (17.6%). On multivariable analysis, reduced preoperative glomerular filtration rate (odds ratio [OR] = 1.45 per 10 mL/min decrease, 95% CI [1.12-1.87], p = 0.004), elevated creatinine (OR = 1.30 per 10 µmol/L increase, 95% CI [1.05-1.61], p = 0.018), prior myocardial infarction (OR = 2.25, 95% CI [1.10-4.62], p = 0.027), and postoperative urinary tract infection (OR = 3.10, 95% CI [1.65-5.82], p < 0.001) were independent predictors. Most strictures were left-sided. Intracorporeal robotic diversion had a higher, though non-significant, stricture rate (21.5% vs. 15.2%, OR = 1.52, p = 0.12). Stricture rates fell markedly after 20 robotic cases per surgeon (23.8% vs. 12.1%).</p><p><strong>Conclusion: </strong>Uretero-enteric strictures are multifactorial, strongly influenced by baseline renal function, cardiovascular comorbidity, and postoperative infection. Robotic intracorporeal diversion shows a learning curve effect, underlining the importance of surgical expertise and infection prevention in reducing risk.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"155-163"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Double blind-ending ureter: diagnostic challenges and robotic-assisted surgical management-case report.","authors":"Marco Di Mitri, Edoardo Collautti, Cristian Bisanti, Andrea Zulli, Alberto Mantovani, Annalisa Di Carmine, Michelangelo Baldazzi, Roberto Lo Piccolo, Riccardo Coletta, Lorenzo Masieri, Mario Lima","doi":"10.32604/cju.2025.067303","DOIUrl":"10.32604/cju.2025.067303","url":null,"abstract":"<p><strong>Background: </strong>Double blind-ending ureter (DBU) is an extremely rare congenital anomaly involving a duplicated ureter with no connection to the renal pelvis or bladder, making diagnosis difficult.</p><p><strong>Case description: </strong>A 10-year-old girl presented with recurrent abdominal pain and ultrasound evidence of left hydroureteronephrosis. Magnetic resonance imaging (MRI) and three-dimensional (3D) reconstruction revealed a 30 cm blind-ending ureter. Robotic-assisted excision (Da Vinci Xi) was performed safely, preserving adjacent structures. Histology confirmed a nonfunctional ureteral remnant.</p><p><strong>Conclusions: </strong>DBU is a rare duplication variant. Advanced imaging and robotic surgery are essential for accurate diagnosis and effective, minimally invasive treatment.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"185-192"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged survival and risk factors for reintervention after inflatable penile prosthesis implantation.","authors":"Skander Zouari, Flora Barthe, Arnoult Morrone, Lionel Mendel, Imad Bentellis, Louis Vignot, Romain Haider, Younes Ahallal, Daniel Chevallier, Matthieu Durand","doi":"10.32604/cju.2025.064281","DOIUrl":"10.32604/cju.2025.064281","url":null,"abstract":"<p><strong>Background: </strong>Inflatable Penile Prosthesis (IPP) is the treatment for erectile dysfunction (ED) refractory to pharmacological therapies. Long-term data on factors associated with prosthesis survival remain unclear. This study aimed to analyze the long-term survival of penile prostheses and identify risk factors associated with survival without reintervention.</p><p><strong>Methods: </strong>This is a retrospective, single-center study of patients who underwent IPP implantation between January 2014 and December 2022. Preoperative data related to the patient and the etiology of ED, as well as perioperative data, were collected. The primary outcome was survival without reintervention, defined as prosthesis revision or explantation due to mechanical dysfunction or infection. We conducted survival analyses without reintervention and searched for risk factors using a multivariate Cox model.</p><p><strong>Results: </strong>In total, 33 out of 137 patients underwent reintervention (24.1%), including 24 (17.5%) prosthesis revisions and 9 (6.6%) had explantations. Median follow-up was 39 months with an interquartile range (IQR) of 9.00 to 62.00. Median survival without reintervention was 7 years. In univariate analysis, downsizing (p = 0.046) was associated with reintervention. Smoking (p = 0.003) and age (p = 0.034) were associated with prosthesis explantation. The number of implantations (p = 0.009) was associated with prosthesis revision. Multivariate analysis by the Cox model did not identify any independent predictive factors for reintervention.</p><p><strong>Conclusion: </strong>Smoking may play a role in infection post-IPP implantation. Primary implantations seem to be associated with better survival. Adjusting cylinder size, known as downsizing, is likely to be a proxy for the complexity of the procedure and thus linked to earlier reintervention.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"173-184"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA PET/CT-guided pelvic lymph node dissection in patients with unfavorable intermediate- or high-risk prostate cancer.","authors":"Eva Donck, Sofie Verbeke, Pieter De Visschere, Valérie Fonteyne, Charles Van Praet, Kathia De Man, Nicolaas Lumen","doi":"10.32604/cju.2025.068589","DOIUrl":"10.32604/cju.2025.068589","url":null,"abstract":"<p><strong>Objectives: </strong>PSMA PET/CT (Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography) offers improved accuracy in detecting lymph node invasion (LNI) in prostate cancer (PC) patients, potentially reducing the need for extended pelvic lymph node dissection (ePLND). This study aims to evaluate a patient-tailored care pathway in which ePLND is performed only in patients with unfavorable intermediate- or high-risk PC who are deemed at risk for LNI based on PSMA PET/CT findings.</p><p><strong>Methods: </strong>In this interventional cohort study, 81 patients were managed according to the new care pathway. ePLND was omitted in cases of negative PSMA PET/CT findings (N0M0), while those with positive PSMA PET/CT findings (N1M0) underwent ePLND. A comparator group of 81 patients was selected from a prospectively generated database for comparison.</p><p><strong>Results: </strong>The intervention group experienced a 75% reduction in the number of ePLNDs performed compared to the comparator group (p < 0.001). ePLND-related complications were significantly lower in the intervention group (p = 0.008). No significant difference was observed in 3-year biochemical-recurrence free survival (BRFS) between the two groups (p = 0.958).</p><p><strong>Conclusion: </strong>Omitting ePLND in patients with negative PSMA PET/CT findings (N0M0) leads to a substantial reduction in the number of ePLNDs performed, resulting in a decrease in morbidity, without compromising early oncological outcomes.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"83-92"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of water vapor thermal therapy for treating lower urinary tract symptoms in men with localized prostate cancer on active surveillance: a case series.","authors":"Mustufa Babar, Farooz Babar, Noah Hawks-Ladds, Justin Loloi, Michael Ciatto","doi":"10.32604/cju.2025.066654","DOIUrl":"10.32604/cju.2025.066654","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is a common malignancy, with many men on active surveillance for localized, low-risk disease also experiencing lower urinary tract symptoms (LUTS) from benign prostatic hyperplasia (BPH). Water Vapor Thermal Therapy (WVTT) is a minimally invasive BPH treatment, but its safety and efficacy in this setting are unclear.</p><p><strong>Case description: </strong>We report three men with localized PCa on active surveillance who underwent WVTT for LUTS.</p><p><strong>Conclusions: </strong>WVTT appears safe and potentially effective in treating LUTS, especially in those with lower-risk disease and smaller prostate volumes. Further research is needed to confirm safety, efficacy, and optimal patient selection.</p>","PeriodicalId":520500,"journal":{"name":"The Canadian journal of urology","volume":"33 1","pages":"193-199"},"PeriodicalIF":0.0,"publicationDate":"2026-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}